MSF launches challenge to Pfizer’s patent on pneumonia vaccine in India

The pneumonia vaccine accounts for almost half the price of vaccinating a child in the poorest countries


Médecins Sans Frontières/Doctors Without Borders (MSF) has filed a ‘patent opposition' in India to prevent US pharmaceutical company Pfizer from getting a patent on the pneumococcal conjugate vaccine (PCV13), so more affordable versions can become available to developing countries and humanitarian organizations.

This is the first time a vaccine (biosimilar) patent has been challenged in India by a medical organization, with the goal of millions more children being protected against deadly pneumonia.

Pneumonia is the leading cause of childhood death, killing almost one million children each year.

Currently, pharmaceutical companies Pfizer and GlaxoSmithKline (GSK) are the only two manufacturers of the vaccine, which could prevent a large number of these deaths.

Pfizer has priced PCV13 (marketed as Prevenar) out of reach of many developing countries and humanitarian organizations.


Previous 1 3 4 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email